Navigation Links
Immune therapy for advanced bladder cancer yields promising results
Date:5/31/2014

New Haven, Conn. A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago.

The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 is a protein expressed by many tumor types that can render the cancer invulnerable to immune attack. The patients in the study were treated with MPDL3280A, a drug being developed by Genentech, a member of the Roche group.

At six weeks, the objective response rate (ORR) was 43%; at 12 weeks, the ORR was 52% in patients with PD-L1-positive tumors. A complete response one showing no evidence of tumors was seen in 7% of PD-L1 patients. In patients with PD-L1-negative tumors, the response rate was 11%.

The results in advanced bladder cancer patients "point to a new era in cancer treatment for a disease that has not seen a major advancement since the introduction of cisplatin-based combination therapy in the 1980s," said the study's senior author Daniel P. Petrylak, M.D., professor of medicine and urology at Yale Cancer Center and Yale School of Medicine. "We look forward to opening the phase II trial at Yale in June to confirm these findings."

Yale Cancer Center enrolled 12 of the 68 patients on the trial at Smilow Cancer Hospital at Yale-New Haven.


'/>"/>

Contact: Vicky Agnew
vicky.agnew@yale.edu
843-697-6208
Yale University
Source:Eurekalert

Page: 1

Related medicine news :

1. How does the immune system fight off threats to the brain? New research yields fresh insight
2. Regulatory immune cell diversity tempers autoimmunity in rheumatoid arthritis
3. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
4. Rutgers team discovers novel approach to stimulate immune cells
5. Scientists study serious immune malfunction
6. Babies susceptibility to colds linked to immune response at birth
7. Reactions to HIV drug have autoimmune cause, reports AIDS journal
8. First study to suggest that the immune system may protect against Alzheimers changes in humans
9. Belly Membrane May Regulate Immune System, Mouse Study Finds
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Researchers reveal crucial immune fighter role of the STING protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International ... company, announced today that its iClinic V12.2 solution has achieved approval from National ... recently introduced PCMH 2017 standards which emphasize team-based care with a significant focus ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network and the ... D’Achille Center for Women’s Behavioral Health at West Penn Hospital , a unique ... women suffering from pregnancy-related depression. Construction of the Center is underway with a ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population Health, ... in KLAS category winner, has named Daniel P. Bullington as chief technology officer. ... technology platform and product offerings,” says Justin Neece, president. “Daniel is an excellent ...
(Date:5/23/2017)... ... ... London, May 23, 2017: Walter Schindler, the Founder and Managing Partner of ... and Contributor to a weeklong series of classes, meetings, field trips and special events ... Schindler and SAIL Capital have received an increasing number of awards ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
(Date:5/3/2017)... May 3, 2017 A Catheterization Laboratory ... or healthcare facility. Commonly referred to as cath ... with diagnostic imaging technology to give physicians visual ... In these spaces, a team of physicians perform ... percutaneous coronary intervention, congenital heart defect closure, stenotic ...
(Date:5/3/2017)... , May 3, 2017  Getinge, a leading ... to quality enhancement and cost efficiency within healthcare ... study of contemporary practice demonstrating that intra-aortic balloon ... for critically ill patients. The single-center, retrospective, observational ... large volume MEGA ® 50cc intra-aortic balloon ...
Breaking Medicine Technology: